Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Leukemia, Myeloid, Acute 101Leukemia 98Precursor Cell Lymphoblastic Leukemia-Lymphoma 95Myelodysplastic Syndromes 83Leukemia, Lymphocytic, Chronic, B-Cell 78Lymphoma, Non-Hodgkin 76Multiple Myeloma 67Hodgkin Disease 67Lymphoma, Mantle-Cell 63Lymphoma 62Lymphoma, Large B-Cell, Diffuse 60Lymphoma, Follicular 59Leukemia, Myeloid, Chronic-Phase 57Lymphoma, B-Cell, Marginal Zone 53Burkitt Lymphoma 53Lymphoma, Large-Cell, Immunoblastic 49Leukemia, Myeloid, Accelerated Phase 48Congenital Abnormalities 48Myeloproliferative Disorders 46Leukemia, Myelomonocytic, Chronic 43Anemia, Refractory, with Excess of Blasts 41Graft vs Host Disease 37Leukemia, Myelogenous, Chronic, BCR-ABL Positive 36Blast Crisis 33Recurrence 32Dendritic Cell Sarcoma, Interdigitating 32Primary Myelofibrosis 27Lymphoma, T-Cell, Cutaneous 27Neoplasms, Plasma Cell 26Waldenstrom Macroglobulinemia 25

Interventions

Docetaxel 277Prednisone 237enzalutamide 177Leuprolide 172Radiotherapy 164Abiraterone Acetate 154Magnetic Resonance Spectroscopy 147bicalutamide 137Goserelin 134Androgen Antagonists 111Radiosurgery 101acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 100apalutamide 79abiraterone 77gallium 68 PSMA-11 74Specimen Handling 67darolutamide 58Gonadotropin-Releasing Hormone 58Radiation 56Triptorelin Pamoate 53cabazitaxel 50Zoledronic Acid 49pembrolizumab 48Radiotherapy, Intensity-Modulated 47Flutamide 47Brachytherapy 47luprolide acetate gel depot 46Standard of Care 45Carboplatin 44Estramustine 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Prostatic Neoplasms × Cyclosporine × Clear all
NCT00922129 2014-01-14

Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer

St. Joseph's Healthcare Hamilton

Phase 2/3 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT00009750 2013-09-20

Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

National Cancer Institute (NCI)

Phase 1 Unknown
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡